ESR1 and metastatic neoplasm: The median age was 50 years (range, 31–62 years), 86.7% had Eastern Cooperative Oncology Group (ECOG) performance status 0, 73.3% had estrogen-receptor positive tumors, 60.0% presented with “de novo” metastatic disease, and 73.3% had visceral disease (40.0% with liver metastases).